USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
Grants to USA small businesses to develop educational computer games for PreK-12 students and teachers or for informal science education audiences. Eligible games involve science, technology, engineering, and math games and have a focus on biology that addresses health and medicine questions. It is expected that this will enable existing curricula and museum exhibits to be transformed in to educational games that will provide hands on learning experiences for students, teachers, and the community at large.
Serious games are defined as the use of gaming technology to train, educate, and encourage behavioral changes in a virtual world format where progressive learning, feedback on success and user control are combined into an interactive and engaging experience.
It is anticipated that this opportunity will facilitate the translation of new or existing health and medicine-based, P-12 STEM curricula and museum exhibits into educational games that will provide a hands-on, inquiry-based and learning-by-doing experience for students, teachers and the community.
There are three phases to this program. The first two are supported by grant funding.
Phase I. The objective of Phase I is to establish the technical/scientific merit and feasibility of the proposed R/R&D efforts. Preliminary data may be included but are not required. The application should concentrate on R/R&D efforts that will significantly contribute to proving the scientific or technical feasibility of the approach or concept that would be a prerequisite to further support in Phase II.
Phase II. The objective of Phase II is to continue the research or R&D efforts initiated in Phase I. Funding shall be based on the results of Phase I and the scientific and technical merit and commercial potential of the Phase II application.
Phase III. An objective of the SBIR/STTR program is to increase private sector commercialization of innovations derived from Federal R/R&D. During Phase III, the small business concern (SBC) is to pursue commercialization with non-SBIR/STTR funds (either Federal or non-Federal). In some Federal agencies, Phase III may involve follow-on, non-SBIR/STTR funded R&D, or production contracts for products or processes intended for use by the U.S. Government.
The NIH Fast-Track mechanism expedites the decision and award of SBIR and STTR Phase II funding for scientifically meritorious applications that have a high potential for commercialization. Fast-Track incorporates a submission and review process in which both Phase I and Phase II grant applications are submitted and reviewed together. The Specific Aims section of the Phase I portion of a Fast-Track must specify clear, measurable goals (milestones) that should be achieved prior to initiating Phase II work. In addition, as is required for all Phase II applications, the Phase II portion of a Fast-Track application must present a Commercialization Plan (maximum 12 pages) that addresses specific points.
Estimated Size of Grant:
Phase I: up to1 year; Phase ll: up to 2 years.
Telephone: (301) 435-0714
TTY: (301) 451-5936